Nearly three dozen attorneys general are attempting a legal act of theft. This month, attorneys general from 31 states, American Samoa, Guam and the District of Columbia sent a letter to the heads of the U.S. Department of Health and Human Services, the National Institutes of Health and the Food and Drug Administration asking the federal government to revoke Gilead Sciences ’ patent for remdesivir, an antiviral drug shown to reduce mortality in patients with Covid-19.
The attorneys general effectively assert that remdesivir belongs to the government because taxpayers helped fund its development. They allege that Gilead can’t make enough of the drug to meet America’s needs. And they claim that its price, about $3,100 for a five-day course, is too high . . .
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
The Remdesivir Patent Isn’t State Property
Sally C. Pipes
Nearly three dozen attorneys general are attempting a legal act of theft. This month, attorneys general from 31 states, American Samoa, Guam and the District of Columbia sent a letter to the heads of the U.S. Department of Health and Human Services, the National Institutes of Health and the Food and Drug Administration asking the federal government to revoke Gilead Sciences ’ patent for remdesivir, an antiviral drug shown to reduce mortality in patients with Covid-19.
The attorneys general effectively assert that remdesivir belongs to the government because taxpayers helped fund its development. They allege that Gilead can’t make enough of the drug to meet America’s needs. And they claim that its price, about $3,100 for a five-day course, is too high . . .
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.